Gholiha A, Hollander P, Lof L, Glimelius I, Hedstrom G, Molin D
Br J Haematol. 2022; 197(5):580-589.
PMID: 35301709
PMC: 9310712.
DOI: 10.1111/bjh.18137.
Pei F, Yu Y, Dong B, Guan H, Dong X, Zhao F
Front Pharmacol. 2021; 12:694545.
PMID: 34867316
PMC: 8635017.
DOI: 10.3389/fphar.2021.694545.
Johnston P, Pinter-Brown L, Warsi G, White K, Ramchandren R
Exp Hematol Oncol. 2018; 7:12.
PMID: 29774169
PMC: 5948762.
DOI: 10.1186/s40164-018-0103-z.
Hassan A, Siddique M, Bashir H, Riaz S, Wali R, Mahreen A
Eur J Nucl Med Mol Imaging. 2017; 44(7):1198-1206.
PMID: 28229191
DOI: 10.1007/s00259-017-3647-y.
Campbell J, Soliman A, Kahesa C, Harlow S, Msemo D
Infect Agent Cancer. 2016; 11:58.
PMID: 27895703
PMC: 5117569.
DOI: 10.1186/s13027-016-0106-5.
Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma.
Fabritius G, Brix G, Nekolla E, Klein S, Popp H, Meyer M
Sci Rep. 2016; 6:35181.
PMID: 27748377
PMC: 5066222.
DOI: 10.1038/srep35181.
Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L, Montravers F, Balogova S, Ragu C, Pacquement H, Leblanc T
Eur J Nucl Med Mol Imaging. 2015; 43(7):1220-30.
PMID: 26660144
DOI: 10.1007/s00259-015-3280-6.
[Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
Liu H, Li H, Xiong W, Yi S, Zou D, Qiu L
Zhonghua Xue Ye Xue Za Zhi. 2015; 36(7):578-82.
PMID: 26304082
PMC: 7342643.
DOI: 10.3760/cma.j.issn.0253-2727.2015.07.011.
Primary nodular lymphocyte-predominant Hodgkin lymphoma of uterine cervix mimicking leiomyoma.
Li W, Wang R, Wang J, Chang K
Clin Case Rep. 2015; 3(6):349-52.
PMID: 26185626
PMC: 4498840.
DOI: 10.1002/ccr3.246.
Endovascular stenting in malignant obstruction of superior vena cava.
Hamzik J, Chudej J, Dzian A, Sokol J, Kubisz P
Int J Surg Case Rep. 2015; 13:84-7.
PMID: 26150051
PMC: 4529653.
DOI: 10.1016/j.ijscr.2015.06.017.
The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?.
Witkowska M, Majchrzak A, Smolewski P
Biomed Res Int. 2015; 2015:485071.
PMID: 25705661
PMC: 4331316.
DOI: 10.1155/2015/485071.
Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading.
Weisshaupt C, Hitz F, Albrich W, Omlin A
BMJ Case Rep. 2014; 2014.
PMID: 25246471
PMC: 4173224.
DOI: 10.1136/bcr-2014-206034.
Primary adrenal nodular lymphocyte-predominant Hodgkin lymphoma: A case report and review of the literature.
Wang J, Ma J, Hu C, Li D, She X
Oncol Lett. 2014; 8(3):1147-1150.
PMID: 25120675
PMC: 4114715.
DOI: 10.3892/ol.2014.2289.
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
Barrington S, George Mikhaeel N, Kostakoglu L, Meignan M, Hutchings M, Mueller S
J Clin Oncol. 2014; 32(27):3048-58.
PMID: 25113771
PMC: 5015423.
DOI: 10.1200/JCO.2013.53.5229.
Patients with AIDS-defining cancers are not universally screened for HIV: a 10-year retrospective analysis of HIV-testing practices in a Swiss university hospital.
Mosimann V, Cavassini M, Hugli O, Mamin R, Achtari C, Peters S
HIV Med. 2014; 15(10):631-4.
PMID: 25102762
PMC: 4232905.
DOI: 10.1111/hiv.12181.
Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.
Law M, Ng T, Chan H, Lai H, Ha C, Leung C
Arch Med Sci. 2014; 10(3):498-504.
PMID: 25097580
PMC: 4107256.
DOI: 10.5114/aoms.2014.43744.
Prognostic factors in hodgkin lymphoma.
Cuccaro A, Bartolomei F, Cupelli E, Galli E, Giachelia M, Hohaus S
Mediterr J Hematol Infect Dis. 2014; 6(1):e2014053.
PMID: 25045461
PMC: 4103502.
DOI: 10.4084/MJHID.2014.053.
Chemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapy.
Yahalom J
Curr Hematol Malig Rep. 2014; 9(3):212-6.
PMID: 24939521
PMC: 4180027.
DOI: 10.1007/s11899-014-0222-5.
Severe neurotoxicity due to Vinblastine in Hodgkin lymphoma.
Suresh P, Kapoor R, Kapur B
South Asian J Cancer. 2014; 3(2):147-8.
PMID: 24818120
PMC: 4014655.
DOI: 10.4103/2278-330X.130492.
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.
Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O
Eur J Nucl Med Mol Imaging. 2014; 41(9):1735-43.
PMID: 24811577
DOI: 10.1007/s00259-014-2783-x.
